1
|
Vantaggiato C, Dell’Omo G, Ramachandran B, Manni I, Radaelli E, Scanziani E, Piaggio G, Maggi A, Ciana P. Bioluminescence imaging of estrogen receptor activity during breast cancer progression. Am J Nucl Med Mol Imaging 2016; 6:32-41. [PMID: 27069764 PMCID: PMC4749503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Accepted: 09/25/2015] [Indexed: 06/05/2023]
Abstract
Estrogen receptors (ER) are known to play an important regulatory role in mammary gland development as well as in its neoplastic transformation. Although several studies highlighted the contribution of ER signaling in the breast transformation, little is known about the dynamics of ER state of activity during carcinogenesis due to the lack of appropriate models for measuring the extent of receptor signaling in time, in the same animal. To this aim, we have developed a reporter mouse model for the non-invasive in vivo imaging of ER activity: the ERE-Luc reporter mouse. ERE-Luc is a transgenic mouse generated with a firefly luciferase (Luc) reporter gene driven by a minimal promoter containing an estrogen responsive element (ERE). This model allows to measure receptor signaling in longitudinal studies by bioluminescence imaging (BLI). Here, we have induced sporadic mammary cancers by treating systemically ERE-Luc reporter mice with DMBA (9,10-dimethyl 1,2-benzanthracene) and measured receptor signaling by in vivo imaging in individual animals from early stage until a clinically palpable tumor appeared in the mouse breast. We showed that DMBA administration induces an increase of bioluminescence in the whole abdominal area 6 h after treatment, the signal rapidly disappears. Several weeks later, strong bioluminescence is observed in the area corresponding to the mammary glands. In vivo and ex vivo imaging analysis demonstrated that this bioluminescent signal is localized in the breast area undergoing neoplastic transformation. We conclude that this non-invasive assay is a novel relevant tool to identify the activation of the ER signaling prior the morphological detection of the neoplastic transformation.
Collapse
Affiliation(s)
- Cristina Vantaggiato
- Department of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, University of Milan20133, Milan, Italy
| | - Giulia Dell’Omo
- Department of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, University of Milan20133, Milan, Italy
| | - Balaji Ramachandran
- Department of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, University of Milan20133, Milan, Italy
| | - Isabella Manni
- Department of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer InstituteVia Elio Chianesi 53, 00144, Rome, Italy
| | - Enrico Radaelli
- Mouse & Animal Pathology Lab, Fondazione Filarete Viale Ortles22/4 - 20139, Milano, Italy
| | - Eugenio Scanziani
- Mouse & Animal Pathology Lab, Fondazione Filarete Viale Ortles22/4 - 20139, Milano, Italy
| | - Giulia Piaggio
- Department of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer InstituteVia Elio Chianesi 53, 00144, Rome, Italy
| | - Adriana Maggi
- Department of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, University of Milan20133, Milan, Italy
| | - Paolo Ciana
- Department of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, University of Milan20133, Milan, Italy
| |
Collapse
|
3
|
Bartolomucci A, La Corte G, Possenti R, Locatelli V, Rigamonti AE, Torsello A, Bresciani E, Bulgarelli I, Rizzi R, Pavone F, D’Amato FR, Severini C, Mignogna G, Giorgi A, Schininà ME, Elia G, Brancia C, Ferri GL, Conti R, Ciani B, Pascucci T, Dell’Omo G, Muller EE, Levi A, Moles A. TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc Natl Acad Sci U S A 2006; 103:14584-9. [PMID: 16983076 PMCID: PMC1600003 DOI: 10.1073/pnas.0606102103] [Citation(s) in RCA: 117] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The vgf gene has been identified as an energy homeostasis regulator. Vgf encodes a 617-aa precursor protein that is processed to yield an incompletely characterized panel of neuropeptides. Until now, it was an unproved assumption that VGF-derived peptides could regulate metabolism. Here, a VGF peptide designated TLQP-21 was identified in rat brain extracts by means of immunoprecipitation, microcapillary liquid chromatography-tandem MS, and database searching algorithms. Chronic intracerebroventricular (i.c.v.) injection of TLQP-21 (15 mug/day for 14 days) increased resting energy expenditure (EE) and rectal temperature in mice. These effects were paralleled by increased epinephrine and up-regulation of brown adipose tissue beta2-AR (beta2 adrenergic receptor) and white adipose tissue (WAT) PPAR-delta (peroxisome proliferator-activated receptor delta), beta3-AR, and UCP1 (uncoupling protein 1) mRNAs and were independent of locomotor activity and thyroid hormones. Hypothalamic gene expression of orexigenic and anorexigenic neuropeptides was unchanged. Furthermore, in mice that were fed a high-fat diet for 14 days, TLQP-21 prevented the increase in body and WAT weight as well as hormonal changes that are associated with a high-fat regimen. Biochemical and molecular analyses suggest that TLQP-21 exerts its effects by stimulating autonomic activation of adrenal medulla and adipose tissues. In conclusion, we present here the identification in the CNS of a previously uncharacterized VGF-derived peptide and prove that its chronic i.c.v. infusion effected an increase in EE and limited the early phase of diet-induced obesity.
Collapse
Affiliation(s)
- A. Bartolomucci
- Institute of Neuroscience, Consiglio Nazionale delle Ricerche, 00143 Rome, Italy
- To whom correspondence may be addressed. E-mail:
, , or
| | - G. La Corte
- Institute of Neurobiology and Molecular Medicine, Consiglio Nazionale delle Ricerche, 00143 Rome, Italy
| | - R. Possenti
- Institute of Neurobiology and Molecular Medicine, Consiglio Nazionale delle Ricerche, 00143 Rome, Italy
- Department of Neuroscience, University of Roma II–Tor Vergata, 00161 Rome, Italy
| | - V. Locatelli
- Department of Experimental and Environmental Medicine and Biotechnology and Interdepartmental Center for Bioinformatics and Proteomics, University of Milan–Bicocca, 20052 Monza, Italy
| | - A. E. Rigamonti
- Department of Pharmacology, Chemotherapy, and Medical Toxicology, University of Milan, 20129 Milan, Italy
| | - A. Torsello
- Department of Experimental and Environmental Medicine and Biotechnology and Interdepartmental Center for Bioinformatics and Proteomics, University of Milan–Bicocca, 20052 Monza, Italy
| | - E. Bresciani
- Department of Experimental and Environmental Medicine and Biotechnology and Interdepartmental Center for Bioinformatics and Proteomics, University of Milan–Bicocca, 20052 Monza, Italy
| | - I. Bulgarelli
- Department of Experimental and Environmental Medicine and Biotechnology and Interdepartmental Center for Bioinformatics and Proteomics, University of Milan–Bicocca, 20052 Monza, Italy
| | - R. Rizzi
- Department of Neuroscience, University of Roma II–Tor Vergata, 00161 Rome, Italy
| | - F. Pavone
- Institute of Neuroscience, Consiglio Nazionale delle Ricerche, 00143 Rome, Italy
| | - F. R. D’Amato
- Institute of Neuroscience, Consiglio Nazionale delle Ricerche, 00143 Rome, Italy
| | - C. Severini
- Institute of Neurobiology and Molecular Medicine, Consiglio Nazionale delle Ricerche, 00143 Rome, Italy
| | - G. Mignogna
- Department of Biochemical Science, University “La Sapienza,” 00185 Rome, Italy
| | - A. Giorgi
- Department of Biochemical Science, University “La Sapienza,” 00185 Rome, Italy
| | - M. E. Schininà
- Department of Biochemical Science, University “La Sapienza,” 00185 Rome, Italy
| | - G. Elia
- Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Eidgenössische Technische Hochschule Zürich, CH-8093 Zürich, Switzerland
| | - C. Brancia
- NEF Laboratory, Department of Cytomorphology, University of Cagliari, 09042 Monserrato, Italy
| | - G.-L. Ferri
- NEF Laboratory, Department of Cytomorphology, University of Cagliari, 09042 Monserrato, Italy
| | - R. Conti
- Department of Endocrinology and Metabolism, Sigma-Tau Pharmaceuticals Industries S.p.A., 00040 Rome, Italy
| | - B. Ciani
- Department of Endocrinology and Metabolism, Sigma-Tau Pharmaceuticals Industries S.p.A., 00040 Rome, Italy
| | - T. Pascucci
- Foundation Santa Lucia, 00143 Rome, Italy; and
| | - G. Dell’Omo
- Institute of Anatomy and Center for Neuroscience, University of Zürich, CH-8057 Zürich, Switzerland
| | - E. E. Muller
- Department of Pharmacology, Chemotherapy, and Medical Toxicology, University of Milan, 20129 Milan, Italy
| | - A. Levi
- Institute of Neurobiology and Molecular Medicine, Consiglio Nazionale delle Ricerche, 00143 Rome, Italy
- To whom correspondence may be addressed. E-mail:
, , or
| | - A. Moles
- Institute of Neuroscience, Consiglio Nazionale delle Ricerche, 00143 Rome, Italy
- To whom correspondence may be addressed. E-mail:
, , or
| |
Collapse
|